17:33 , Feb 8, 2018 |  BC Extra  |  Politics & Policy

FDA facilitating generic versions of complex drugs

FDA released new guidance documents Thursday that are intended to facilitate generic competition for “complex,” hard-to-copy drugs. It issued product-specific guidance on 19 complex medicines, including six that have no generic competition. The drugs are...
07:00 , Mar 9, 2009 |  BC Week In Review  |  Company News

Bausch & Lomb, Pfizer sales and marketing update

Under a five-year deal, the partners will co-promote each other's ophthalmic drugs in the U.S. The deal includes Pfizer's Xalatan latanoprost and Bausch & Lomb's Alrex and Lotemax loteprednol etabonate products,...
07:00 , Oct 15, 2001 |  BC Week In Review  |  Company News

Pharmos, Bausch & Lomb Inc. deal

PARS sold its loteprednol etabonate (LE) ophthalmic business to BOL. BOL paid $25 million in cash for PARS’s Lotemax and Alrex, which BOL already markets under a 1995 deal, and BOL is acquiring...
07:00 , Oct 10, 2001 |  BC Extra  |  Company News

Pharmos sells ophthalmics to BOL

PARS sold its loteprednol etabonate (LE) ophthalmic business to Bausch & Lomb (BOL). BOL paid $25 million in cash for PARS's Lotemax and Alrex, which BOL already markets under a 1995 deal, and BOL is...
07:00 , Sep 5, 2000 |  BC Week In Review  |  Company News

Pharmos, Senju deal

PARS granted Senju rights in Japan, Korea and Australia to its loteprednol etabonate formulation patent in exchange for a $400,000 upfront payment and single-digit royalties. Loteprednol, an ophthalmic anti-inflammatory, is sold in the U.S. under...
08:00 , Mar 16, 1998 |  BioCentury  |  Finance

Glaxo thinks ROI

Glaxo thinks ROI Glaxo's planned purchase of $50 million in Affymetrix preferred stock is a pure investment play, according to both sides of the deal (B12). Glaxo already owns 33 percent of AFFX through its...
08:00 , Mar 16, 1998 |  BC Week In Review  |  Clinical News

Pharmos, Bausch & Lomb Pharmaceuticals Inc. regulatory update

The FDA approved PARS's Lotemax and Alrex, compounds that incorporate loteprednol etabonate, a site-specific steroid. Lotemax was approved to treat post-operative eye inflammation while Alrex treats allergic conjunctivitis and eye inflammation, Bausch &...